Article:

PIONEERING PROGRESS IN ALZHEIMER'S CLINICAL TRIALS

As global challenges in Alzheimer's clinical development persist, CROs must leverage their comprehensive expertise to navigate the intricate landscape of neurodegenerative research.

In the ever-evolving field of Alzheimer's disease (AD) research, the quest for effective treatments remains a formidable challenge. As AD programs move from discovery into human studies, the scientific promise of a mechanism often collides with one of the most unforgiving clinical development landscapes: uncertain pathophysiology, heterogeneous natural history, time-consuming study procedures, new biomarkers and endpoint measures with challenging clinimetric characteristics.

UNDERSTANDING THE COMPLEXITY OF ALZHEIMER'S RESEARCH

Alzheimer's Disease is a progressive neurodegenerative disorder affecting millions globally, with numbers projected to soar in the coming decades.[1] Despite extensive research and recent advances with the approval of the anti-amyloid therapies, the path to effective treatment is fraught with complexities. Sponsors must tightly connect disease biology, mechanism of action, therapeutic platform, route of administration, and expected exposure–response to reduce late-stage attrition.[2,3]

A growing body of work maps AD along a continuum from preclinical to dementia, linking amyloid and tau pathology, neurodegeneration, and clinical symptoms. Reviews of AD biomarkers now describe a "biological definition" of disease anchored in amyloid (A), tau (T), neurodegeneration (N) markers and neuroinflammation (NI), with fluid and imaging assays available across stages (Alzheimer's Dement (N Y), 2026).[4,5] Positioning an asset within this framework informs dose selection, inclusion criteria, and realistic expectations for effect size and timing.

Program success increasingly depends on using preclinical and translational data to justify the leap into Phase 1. For example, an antibody targeting soluble amyloid species should be supported by in vitro binding data, animal models showing plaque reduction or downstream functional changes, and early human data that demonstrate central target engagement. Structured decision trees linking each development milestone to pre-defined biological and pharmacokinetic/pharmacodynamic (PK/PD) thresholds can prevent progression of assets with weak mechanistic plausibility.[6]

Alzheimer's disease is characterized by multiple pathophysiological processes, and the majority of patients present with mixed pathologies, while comorbidities also play a role in each individual clinical evolution. These pathological hallmarks are interconnected and contribute to the progression of the disease.

Combination therapy for AD aims to address these complex pathologies by targeting multiple pathways or the same pathway at different points. This approach is supported by evidence from neuropathologic, biomarker, and genetic studies indicating that the disease arises from the interaction of multiple complex and overlapping pathophysiological pathways.[7,8] The use of two or more disease-modifying agents may allow for smaller and potentially safer doses of each agent, and a sequence of agents may be required across the continuum of disease as the biological mechanisms evolve.

This combination therapy approach is crucial for developing effective treatments for AD — as monotherapies that by themselves have modest clinical effects may, when combined, produce additive or synergistic effects. This makes combination clinical designs even more complex (Alzheimer's Disease Drug Development in an Evolving Therapeutic Landscape, 2024).[9]

Examples from other neurodegenerative indications illustrate this principle. In spinal muscular atrophy, there are three distinct platforms—antisense oligonucleotide, gene therapy, and small molecule splicing modulation[10]—were each grounded in a clear genetic mechanism and a well-characterized natural history, enabling confident dose justification and rapid regulatory review. Applying a similar level of biological rationale in AD helps Sponsors align program scope with true probability of success.

DESIGNING ENRICHED POPULATIONS WITH BIOMARKERS AND CASE DEFINITION

Effective Alzheimer's trials depend on enrolling participants who truly have the pathology that the investigational product is intended to modify. Historically, clinical diagnostic criteria alone produced substantial false positive rates in dementia syndromes, diluting treatment effects, and obscuring otherwise promising signals.

Today, enrichment strategies are possible that rely on convergent biomarker evidence. Amyloid and tau PET, CSF Aβ42/40, and plasma phosphorylated tau (e.g., p-tau217) can substantially increase the likelihood that enrolled participants have underlying AD pathology, even at preclinical and prodromal stages.[11,12,13] Emerging blood-based markers are particularly valuable in large or geographically dispersed trials, reducing screen failure rates and participant burden while preserving specificity.

Thoughtful use of biomarkers also supports sample-size optimization. By narrowing variability in baseline pathology and progression rates, enriched populations can improve statistical power in early-phase trials, allowing smaller, more focused studies that still yield interpretable signals. Sponsors can then reserve larger, more heterogeneous populations for confirmatory work once mechanisms and doses are well established.

However, enrichment must be balanced against feasibility and equity. High-cost imaging or lumbar punctures can limit participation from certain regions, health systems, or groups. Hybrid schemas—using plasma biomarkers for pre-screening, followed by confirmatory CSF or imaging in a subset—can maintain scientific rigor while broadening access and controlling costs.

TIMING AND TREATMENT

Timing of intervention and selecting meaningful outcomes for the temporal dynamics of Alzheimer's pathophysiology pose a second major challenge. Pathological processes begin decades before overt symptoms, yet most historic trials attempted to modify disease at mild-to-moderate dementia stages, where neuronal loss is already advanced and functional decline entrenched.

Recent approvals of anti-amyloid monoclonal antibodies in early symptomatic AD have validated the concept that intervening earlier can shift clinical trajectories, even if the magnitude of benefit remains modest (FDA, 2023).14 These programs combine biomarker-based confirmation of amyloid pathology with cognitive and functional endpoints, offering a template for linking surrogate and clinical measures.

Selecting primary outcomes now requires a deliberate alignment between disease stage, mechanism, and predicted effect. For preclinical or prodromal populations, composite cognitive scores and sensitive functional scales may detect subtle changes over multi-year follow-up.

In more advanced stages, preservation of daily activities, delay in institutionalization, or maintenance of caregiver-reported function may be more realistic and meaningful endpoints.

Equally important is the validation status and regulatory familiarity of chosen tools. Scales such as the Clinical Dementia Rating–Sum of Boxes (CDR-SB) and Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) have extensive historical data, but Sponsors may need to supplement them with digital or performance-based assessments that capture domains like goal-directed behavior, speech, sleep, or social engagement. Any novel or adapted outcome measure should be supported by evidence of reliability, sensitivity to change, and clinical relevance.

Finally, robust endpoint strategies integrate biomarker trajectories, safety signals, and patient-centered outcomes into a coherent interpretation plan. Pre-specified hierarchies and responder definitions can reduce multiplicity concerns and facilitate communication with regulators, payers, and clinicians.

RECRUITMENT, SITE MODELS, AND RETENTION IN FRAGILE POPULATIONS

Operationally, Alzheimer's trials face numerous obstacles during site selection, recruitment, and retention. Many trials compete for the same limited pool of potentially eligible participants, and requirements for study partners, complex imaging, and frequent visits can discourage enrollment. Site strategy is therefore central.

Specialized memory clinics and academic centers offer experienced investigators, established diagnostic pathways, and access to biomarker infrastructure, but they may be over-subscribed. Complementing them with carefully supported community sites, equipped through targeted training and mentorship, can expand reach without sacrificing data quality.

Hub-and-spoke models are increasingly used to connect expert centers with regional clinics or telemedicine networks, enabling participants in underserved areas to join trials. In practical terms, this may mean central biomarker readouts, mobile nursing for safety labs, and Sponsor-supported travel and accommodation. For hyper-rare or geographically dispersed neurodegenerative populations, similar multimodal recruitment strategies have demonstrated on-time enrollment, with participants and families proactively seeking trials once they are aware of the opportunity.

Preclinical Alzheimer's studies require a huge effort as participants don't have cognitive issues or any clinical complaints. They are found in the community, not at clinical sites. These require special strategies, such as implementing family testing or determining if genetic counseling would be included as part of the recruitment efforts of identifying these patients.

Retention planning begins with protocol design. Visit schedules should reflect the cognitive and physical limitations of participants, minimizing full-day assessments and clustering complex procedures when possible. Consistency in raters and site staff can reduce anxiety, improve completion of cognitive batteries, and protect endpoint integrity by limiting inter-rater variability.

Transparent communication with advocacy groups and patient organizations is also essential. These partners bring the lived-experience perspective into discussions on acceptable risk, procedural burden, and informed consent materials, increasing the likelihood that a trial is both scientifically robust and feasible in real-world settings.

CAPACITY, CONSENT, AND ETHICAL INTEGRITY IN GLOBAL STUDIES

Alzheimer's clinical development operates at the intersection of cognitive impairment, evolving capacity, and diverse national regulations on research with vulnerable adults. A defensible and operationally practical consent framework is therefore foundational to any global AD program.

Capacity is task- and time-specific. A participant may be able to provide informed consent at screening but later lose the ability to understand or weigh study information. Protocols should explicitly describe how capacity will be assessed, how often reassessment will occur, and how decisions will transition to legally authorized representatives (LARs) when necessary. Standardized capacity assessment tools, combined with structured investigator training, help ensure consistent application across sites and regions.

Country-specific requirements further complicate implementation. Some jurisdictions mandate LAR consent plus participant's assent when possible; others specify different hierarchies of surrogate decision-makers or additional ethics committee approvals. Knowledge of the ever-evolving regulatory requirements regarding LAR is imperative to ensure the right sites, countries, and regions are chosen for any given trial. Building these nuances into site manuals, templates, and training materials reduces delays and audit findings.

Participant-facing materials—information sheets, videos, visual aids—must be accessible to individuals with cognitive impairment and their families. Plain language descriptions of procedures, risks, and potential benefits, alongside clear explanations of what happens if capacity changes mid-study, support ethically sound decisions.

Case experiences from global neurodegenerative programs show that early, detailed planning of consent pathways can be the difference between a study that struggles at activation and one that proceeds smoothly. Attention to these ethical and legal dimensions also reassures regulators and institutional review boards that vulnerable participants are appropriately safeguarded.

INTEGRATING DATA, SYSTEMS, AND STAKEHOLDERS FOR ENDPOINT PROTECTION

Even well-designed Alzheimer's trials can fail if data capture and operational systems are not aligned with scientific questions. Endpoint protection—ensuring that primary and key secondary outcomes are measured accurately, consistently, and with minimal missingness—requires an integrated approach.

Electronic clinical outcome assessment (eCOA) platforms, interactive response technologies, imaging repositories, and safety monitoring systems should be configured to support, rather than complicate, investigator decision-making. For example, logic checks linking cognitive scores with randomization systems can flag out-of-range or inconsistent data before they compromise stratification or analysis. Similarly, pre-specified scheduling rules in visit management tools can help sites adhere to allowed time windows for key assessments.

Participants may find lengthy visits exhausting. Sequencing cognitive, functional, and safety assessments in a predictable order, delivered by familiar staff, can improve completion rates and reduce noise. Training that emphasizes not only instrument administration, but also rapport-building and environmental control (e.g., minimizing distractions and placebo effect) further enhances data quality.

Finally, the interpretation of trial results benefits from triangulating quantitative outcomes with qualitative insights from sites, caregivers, and participants. Understanding why specific visits were missed, which procedures generated the most anxiety, or how protocol amendments played out operationally can contextualize borderline findings and inform future designs.

THE PATH FORWARD

The future of Alzheimer's research is promising, with ongoing innovations in therapeutic platforms, biomarkers, and trial designs at the helm. Translating breakthroughs into successful clinical programs requires operational excellence, rigorous methodology, and a deep understanding of the patient journey.

Those organizations that combine scientific expertise with practical trial execution will be best positioned to navigate complexity, reduce risk, and advance the next generation of Alzheimer's therapies.

AUTHORS:

Teresa León Colombo MD/PhD, Vice President at **Medpace**, is an accomplished neuroscientist and board-certified neurologist with 30+ years of experience in clinical development, including expertise on rare and neurodegenerative diseases.

Filipe Rodrigues MD/PhD, Senior Medical Director at **Medpace**, has 10+ years of experience in neuroscience clinical development, including rare diseases and neurodegeneration. He is dedicated to providing clinical and scientific expertise and hands-on experience within neurosciences programs.

Guido Moesker MSc, Senior Director, Clinical Trial Management at **Medpace**, is an accomplished clinical research professional with 17 years of clinical research experience and is part of the Neuroscience leadership team within Medpace, focusing on neurodegeneration.

Daniela Rae MSc, RGN, Advanced Clinical Practitioner at **Medpace**, is an accomplished Consultant Nurse with nearly 2 decades of senior clinical, operational, and research leadership experience in neuroscience indications, specializing in neurodegenerative and neuropsychiatric disease.

REFERENCES:

1. Visit: 2025 Alzheimer's disease facts and figures - PMC
2. Visit: Considering challenges for the new Alzheimer's drugs: Clinical, population, and health system perspectives - Walsh - 2024 - Alzheimer's & Dementia - Wiley Online Library
3. Visit: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3331862/#:~:text=Sensitivity%20estimates%20have%20ranged%20between,of%20AD%20is%20extremely%20accurate.
4. Visit: https://www.neurology.org/doi/10.1212/WNL.0000000000002350
5. Visit: Frontiers | The 2024 NIA-AA biological definition of Alzheimer's disease: linking biomarkers to clinical practice
6. Visit: Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges - PMC
7. Visit: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.712565/full
8. Visit: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120398/
9. Visit: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70015
10. Visit: Targeted antisense oligonucleotide treatment rescues developmental alterations in spinal muscular atrophy organoids | Nature Communications
11. Visit: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/209531Orig1s000ltr.pdf
12. Visit: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213535Orig1s000ltr.pdf
13. Visit: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213535Orig1s000ltr.pdf
14. Visit: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene